Research
BT-115386, a MAT2A inhibitor, targets MTAP-deficient nasopharyngeal carcinoma via c-Myc and p53 modulation
Cell Reports Medicine · By Yuk-Yu Chan, Man Wu, Grace Tin Yun Chung, Yi Zhang, Ming-Ting Liu, Xiaodong Zhang, Qian Wu, Shinyee Hui, Bo Wang, Eeling Kong, Melissa Sue Ann Chan, Hei-Man Leung, Ying Cong, Ka-Fai To, David Johnson, Brigette Buig Yue Ma, Jun Tang, Kwok-Wai Lo & Chi-Man Tsang ·
The Brief
- MTAP homozygous deletion occurs in 37.5% of Epstein-Barr virus-associated nasopharyngeal carcinomas, according to the source.
- Chan et al. report that the oral MAT2A inhibitor BT-115386 achieved robust tumor suppression in nasopharyngeal carcinoma.
- The authors state that BT-115386 works by targeting PRMT5 to degrade c-Myc and restore p53 signaling.
Why it matters
The study points to MTAP deficiency as a possible patient-selection marker for MAT2A or PRMT5-pathway drugs in a cancer type where it is common. Readers should note that the source describes the mechanism but does not report clinical outcomes.
Who’s affected
- cancer researchers studying nasopharyngeal carcinoma
- oncology drug developers working on MTAP-deficient tumors
- #nasopharyngeal carcinoma
- #mat2a
- #mtap deficiency
- #prmt5
- #cancer therapy
MTAP homozygous deletion occurs in 37.5% of Epstein-Barr virus-associated nasopharyngeal carcinomas (NPCs). Chan et al. demonstrate that the oral MAT2A inhibitor BT-115386 achieves robust tumor suppression by targeting PRMT5 to degrade c-Myc and restore p53 signaling in NPC…